1-4 of 4
Winfried Wels
Close
Sort by
Journal Articles

CMV-Specific Cytokine-Induced Killer Cells Comprise Concomitant Cytotoxicity Against Leukemia and Cytomegalovirus

Verena Pfirrmann, Sarah Oelsner, Eva Rettinger, MD, Sabine Huenecke, PhD, Jindrich Cinatl, Prof., Winfried Wels, Prof., Thomas Klingebiel, Prof., Peter Bader
Journal: Blood
Blood (2014) 124 (21): 5814.
https://doi.org/10.1182/blood.V124.21.5814.5814
Published: 2014
Journal Articles

Development of Retargeted CD38-Specific NK-92 Cell Line for Potential Anti-Myeloma Immunotherapy.

Shihong Yang, MMed, Xin An, PhD, Ross D. Brown, PhD, Joy Ho, PhD, John Gibson, PhD, Douglas E. Joshua, PhD, Winfried Wels, PhD, Daniel M. Sze, PhD
Journal: Blood
Blood (2005) 106 (11): 5104.
https://doi.org/10.1182/blood.V106.11.5104.5104
Published: 2005
Journal Articles

Re-Targeting of an NK Cell Line (NK92) with Specificity for CD19 Efficiently Kills Human B-Precursor Leukemia Cells.

Annette Romanski, Christoph Uherek, Gesine Bug, Tina Muller, Claudia Rossig, Manuela Kampfmann, Nicola Krossok, Dieter Hoelzer, Erhard Seifried, Winfried Wels, Oliver G. Ottmann, Torsten Tonn
Journal: Blood
Blood (2004) 104 (11): 2747.
https://doi.org/10.1182/blood.V104.11.2747.2747
Published: 2004
Journal Articles

Retargeting of natural killer–cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction

Christoph Uherek, Torsten Tonn, Barbara Uherek, Sven Becker, Barbara Schnierle, Hans-Georg Klingemann, Winfried Wels
Journal: Blood
Blood (2002) 100 (4): 1265–1273.
https://doi.org/10.1182/blood.V100.4.1265.h81602001265_1265_1273
Published: 2002